Literature DB >> 22168412

Microbes and microbial effector molecules in treatment of inflammatory disorders.

Denise Kelly1, Margaret I Delday, Imke Mulder.   

Abstract

The healthy gut tolerates very large numbers of diverse bacterial species belonging mainly to the Bacteroidetes and Firmicutes phyla. These bacteria normally coexist peacefully with the gut and help maintain immune homeostasis and tolerance. The mechanisms promoting tolerance affect various cell populations, including the epithelial cells lining the gut, resident dendritic cells (DCs), and gut-homing T cells. Gut bacteria also influence multiple signaling pathways from Toll-like receptors to nuclear factor κB and regulate the functionality of DCs and T cells. Several bacterial species have been identified that promote T-cell differentiation, in particular T-helper 17 and T-regulatory cells. Insight into the molecular mechanisms by which bacteria mediate these effects will be very important in identifying new ways of treating intestinal and extra-intestinal immune-mediated diseases. These diseases are increasing dramatically in the human population and require new treatments. It may be possible in the future to identify specific bacterial species or strains that can correct for T-cell imbalances in the gut and promote immune homeostasis, both locally and systemically. In addition, new information describing microbial genomes affords the opportunity to mine for functional genes that may lead to new generation drugs relevant to a range of inflammatory disease conditions.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22168412     DOI: 10.1111/j.1600-065X.2011.01079.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  7 in total

1.  Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.

Authors:  Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Nitric oxide-driven hypoxia initiates synovial angiogenesis, hyperplasia and inflammatory lesions in mice.

Authors:  Fei Bao; Pei Wu; Na Xiao; Frank Qiu; Qing-Ping Zeng
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

3.  Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota.

Authors:  Bartholomeus van den Bogert; Marjolein Meijerink; Erwin G Zoetendal; Jerry M Wells; Michiel Kleerebezem
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

4.  Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells.

Authors:  Malgorzata Nepelska; Tomas de Wouters; Elsa Jacouton; Fabienne Béguet-Crespel; Nicolas Lapaque; Joël Doré; Velmurugesan Arulampalam; Hervé M Blottière
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

5.  Butyrate produced by commensal bacteria potentiates phorbol esters induced AP-1 response in human intestinal epithelial cells.

Authors:  Malgorzata Nepelska; Antonietta Cultrone; Fabienne Béguet-Crespel; Karine Le Roux; Joël Doré; Vermulugesan Arulampalam; Hervé M Blottière
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

6.  Vitamin D and allergic airway disease shape the murine lung microbiome in a sex-specific manner.

Authors:  Michael Roggenbuck; Denise Anderson; Kenneth Klingenberg Barfod; Martin Feelisch; Sian Geldenhuys; Søren J Sørensen; Clare E Weeden; Prue H Hart; Shelley Gorman
Journal:  Respir Res       Date:  2016-09-21

7.  IL-22 is rapidly induced by Pathogen Recognition Receptors Stimulation in Bone-Marrow-derived Dendritic Cells in the Absence of IL-23.

Authors:  Silvia Fumagalli; Anna Torri; Angela Papagna; Stefania Citterio; Federica Mainoldi; Maria Foti
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.